Session 92 - 12th CROI

Home

Session 92 Poster Abstracts
Immune-Based Therapies
Wednesday, 1:30 - 3:30 pm
Hall A

512	HAART Interruption Blunts but Does Not Abrogate CD4 T-cell Responses to IL-2 Administration in HIV-infected Patients Chris Keh*, J Shen, B Hahn, C Rehm, R Davey, C Lane, and I Sereti NIAID, Bethesda, MD, USA
513	Evaluation of Natural Killer Cells and Expression of NK Cell Receptors in CD8 T Cells after 1 Year of Structured Therapy Interruption G Mestre, Montserrat Plana*, F García, E Martínez, A Milinkovic, E Fumero, P Castro, A Cruceta, J Mallolas, J Blanco, J Miró, T Pumarola, T Gallart, and J Gatell Hosp Clin, IDIBAPS, Univ of Barcelona, Spain
514	Single Supervised Treatment Interruption Coupled with Mycophenolate Mofetil Therapy Induces Control of HIV-1 RNA Replication in Patients Treated with ART since Primary HIV-1 Infection: 102-Week Follow-Up D Ciuffreda¹, G P Rizzardi², C Tassan-Din², G Travi², G Guaraldi³, A Lazzarin², G Pantaleo¹, and Giuseppe Tambussi*² ¹Univ Hosp, Lausanne, Switzerland; ²San Raffaele Sci Inst, Milan, Italy; and ³Unimore, Modena, Italy
515	Use of Interleukin-2 Adjuvant Therapy in the Context of Structured Antiretroviral Treatment Interruption in Patients with Primary HIV Infection Andrea Gori*¹, G Marchetti¹, M Schenal², M Cesari¹, D Trabattoni², A Bandera¹, C Molteni¹, L Meroni¹, M Galli¹, M Moroni¹, M Clerici², and F Franzetti¹ ¹Univ of Milan, Italy and ²Univ of Milan, Italy
516	Interleukin-2 as Treatment for Immunological Discordant Patients with CD4 below 200 Cells/µL after at Least 1 Year of HAART Juan Lopez*¹, J Miro², S Moreno³, R Rubio⁴, B Mahillo⁵, C Cifuentes⁶, V Navarro⁷, J Portilla⁸, J Terron⁹, A Jou¹⁰, C Minguez¹¹, J Arribas¹², P Viciana¹³, A Orti¹⁴, M Ruiz⁵, and Gesida 33/03 Study Group ¹Hosp Univ Gregorio Marañon, Madrid, Spain; ²Hosp Clin, Barcelona, Spain; ³Hosp Ramon y Cajal, Madrid, Spain; ⁴Hosp 12 de Octubre, Madrid, Spain; ⁵AEC-GESIDA, Madrid, Spain; ⁶Hosp Son Llatzer, Mallorca, Spain; ⁷Hosp La Fe, Valencia, Spain; ⁸Hospital General. Alicante. Spain; ⁹Hosp de Jerez, Cadiz, Spain; ¹⁰Hosp Germans Trias i Pujol, Barcelona, Spain; ¹¹Hosp Gen, Castellon, Spain; ¹²Hosp La Paz, Madrid, Spain; ¹³Hosp Virgen del Rocio, Seville, Spain; and ¹⁴Hosp Virgen de la Cinta, Tarragona, Spain
517	Dramatic Induction of Antigen-specific Immune Responses in SIV Infection by a Plasmid IL-12+SIV Antigen DNA Vaccine J Boyer¹, S Kumar¹, S Calarota¹, M Kutzler¹, A Shen², Z Israel³, M Lewis⁴, J Eldridge⁵, R Siliciano², and David Weiner*¹ ¹Univ of Pennsylvania, Philadelphia, USA; ²Johns Hopkins Univ, Baltimore, MD, USA; ³Vaccines Discovery, Wyeth, Pearl River, NY, USA; ⁴Bioqual, Inc, Rockville, MD, USA; and ⁵Vaccines Discovery, Wyeth, MD, USA
518	Viral Load Is Reduced and CD4 Count Increased following Multiple Infusions of Cytolin in Patients with HIV D W Northfelt*¹, G Morrison², and A Allen³ ¹Mayo Clin Coll of Med, Scottsdale, AZ, USA; ²Symbion Res Intl Inc, Agoura Hills, CA, USA; and ³Cytodyn Inc, Santa Fe, NM, USA
519	Impaired Monocyte Maturation in Response to CpG Oligodeoxynucleotide Is Related to Viral RNA Levels in HIV Disease and Is at Least Partially Mediated by Deficiencies in Type I Interferon Responsiveness and Production Wei Jiang*^1,2, M Lederman^1,2, J Salkowitz^1,2, B Rodriguez^1,2, C Harding¹, and S Sieg^1,2 ¹Case Western Reserve Univ, Cleveland, OH, USA and ²Univ Hosp of Cleveland, Ctr for AIDS Res, OH, USA
520	Immune Therapy of Advanced HIV-1 Infection by Transduced Autologous CD4+ T Cells Expressing a Peptide that Inhibits Viral Entry. Results of a Phase I Pilot Study Jan van Lunzen*¹, T Glaunsinger¹, I Stahmer¹, K Kuehlke², A Schilz², N Dinauer³, A Alexandrov³, H J Stellbrink¹, C Mayr⁴, and D von Laer⁵ ¹Univ Clin Eppendorf, Hamburg, Germany; ²Eufets Ltd, Idar Oberstein, Germany; ³Fresenius Biotech Ltd, Bad Homburg, Germany; ⁴Private Practice, Berlin, Germany; and ⁵Univ of Frankfurt, Germany
521	Use of Engineered Zinc Finger-based Endonucleases to Create CCR5 Targeted Gene Disruption in T Cells as Potential Therapy of HIV/AIDS Elena Perez*¹, Y Jouvenot², F Urnov², M Holmes², C Beausejour², J Rock², Y L Lee², J Miller², D Ando², P Gregory², C June¹, and J Riley¹ ¹Univ of Pennsylvania, Philadelphia, USA and ²Sangamo Biosciences, Inc, Richmond, CA, USA
522	Feasibility of a Stem Cell Gene Therapy Approach with Non-Myeloablative Conditioning in Patients with HIV-1 Infection Gian-Paolo Rizzardi*¹, S Nozza², L Turchetto¹, A Harari³, G Tambussi², F Crippa², M Salomoni¹, V Rusconi², S Toma¹, G Pantaleo³, A Lazzarin², and C Bordignon¹ ¹MOLMED, Milan, Italy; ²San Raffaele Sci Inst, Milan, Italy; and ³Univ Hosp, Lausanne, Switzerland
523	Effects on Viral Load and Immunity of a Multiple Vaccination Program in Successfully Treated HIV-infected Adults on HAART Pedro Castro*^1,2, R Gonzalez^1,2, A López^1,2, M Plana^1,2, F García^1,2, E Fumero^1,2, A Vilella^1,2, N Climent^1,2, S Sánchez^1,2, C Gil^1,2, J Miró^1,2, T Gallart^1,2, T Pumarola^1,2, J Bayas^1,2, and J Gatell^1,2 ¹Hosp Clin, IDIBAPS, Univ of Barcelona, Spain and ²Univ of Barcelona, Spain